Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes

This study is looking at how obesity affects insulin action and fitness in people with Type 1 Diabetes. Researchers want to see if a 15-week High-Intensity Interval Training (HIIT) exercise program can improve these factors. You might be able to join if you are between 21 and 50 years old, have Type 1 Diabetes for at least 5 years with an HbA1c (a measure of blood sugar over time) of 8.5% or less, and meet certain body mass index (BMI) requirements. The study will measure changes in blood flow in your muscles and your aerobic fitness before and after the exercise program to see if the intervention is successful. The current recruitment status is unclear.

Study design: This is an interventional study planning to enroll 60 participants. It will compare people with Type 1 Diabetes and healthy controls, both with and without overweight/obesity.
What's involved: Participants will take part in a 15-week HIIT exercise training program. Measurements will be taken before and after this training.
Compensation: Not stated in the trial record.
Follow-up: Participants will be assessed before and after 15 weeks of exercise training.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes

Recruiting

NAAges 21–50InterventionalBasic science

University of Virginia

~60 participants

Updated 2026-05-07 on ClinicalTrials.gov

What's tested:Exercise training

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Microvascular blood volume in skeletal and cardiac muscle - changes from baseline

Measured over Before and after 15 weeks of exercise training

+1 more outcome measured

Conditions

Type 1 Diabetes

Overweight

Where it's being run

1 sites across 1 states

Virginia1

Study leadership

Zhenqi Liu, MD · PRINCIPAL_INVESTIGATOR · University of Virginia

Who to contact

Lee Hartline, MEd

[email protected]

434-924-5247

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

• Male or female ≥21 and ≤50 years old

For persons with T1D: Disease duration ≥ 5 years and HbA1c ≤ 8.5% on multiple daily insulin injection or insulin pump

Body mass index: ≥19 and ≤27 kg/m2 for control and T1D, ≥30 and ≤40 kg/m2 (27.5 to 37.5 for Asian Americans) for obesity and T1D + obesity. BMI is limited to ≤40 kg/m2 (37.5 for Asian Americans) for easier vascular access and cardiac imaging.

Stable use of non-insulin medications for over 6 months other than estrogen/progesterone containing medications which must be discontinued at least 3 months prior to the study (intrauterine devices may be continued due to limited systemic absorption)

Exclusion

• Acute or chronic disease other than T1D or obesity

History of microvascular or macrovascular diabetes complications

History of diabetic ketoacidosis in the past 24 months

History of hypoglycemia unawareness

Recently active (\>20 min of moderate/high intensity exercise, 2 times/week)

Subjects who are smokers or who have quit smoking \<5 years

Subjects with hypertriglyceridemia (\>400 mg/dl)

Current use of vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha- or beta-blockers, or diuretics).

Females taking oral contraceptives in the past 3 months

Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy

Pregnant (as evidenced by positive pregnancy test) or nursing women

Musculoskeletal condition preventing participation in exercise testing or exercise training

History of gastroparesis

Pulse oximetry \<90%

What this trial measures

Microvascular blood volume in skeletal and cardiac muscle - changes from baselineBefore and after 15 weeks of exercise training
insulin-mediated changes in skeletal and cardiac muscle as determined by insulin clamp
maximal aerobic exercise capacitybefore and after 15 weeks of exercise training
change in VO2max

Trialytics